Llopiz and co-workers showed that the application of anti-IL-10 monotherapy did not cause the expected therapeutic results, but its application with adjuvants, was capable of inducing the activation of DCs, which can potentially lead to complete B16 melanoma tumor rejection [35]. Here, IL10 is linked to melanoma.